Search

Your search keyword '"Anna Monter‐Rovira"' showing total 4 results
Start Over "Anna Monter‐Rovira" Topic medicine
4 results on '"Anna Monter‐Rovira"'

1. Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report

Author

Marta Santaliestra, Elena Bussaglia, Marta Pratcorona, Anna Monter‐Rovira, Silvana Saavedra, Anna Mozos, Clara Martínez, and Josep F. Nomdedéu

Subjects
ASXL1, autoimmune, bone marrow fibrosis, molecular, Sjögren syndrome, Medicine, Medicine (General), R5-920
Abstract

Abstract Only proven pathogenic mutations associated with myeloid neoplasms are key to establish the clonal nature of the bone marrow fibrosis. In cases with genetic variants of uncertain meaning, the clinical picture may be required to rule out secondary causes.

Published
2020
Full Text
View/download PDF

2. Ultrastructural, cytogenetic, and molecular findings in mast cell leukemia: Case report

Author

Anna Bosch‐Vilaseca, Anna Monter‐Rovira, Sabina Cisa‐Wieczorek, Guadalupe Oñate, Elena Bussaglia, Maite Carricondo, Ángel Remacha, Clara Martínez, Marta Pratcorona, María Laura Blanco, and Josep F. Nomdedéu

Subjects
acute leukemia, genomics, molecular biology, systemic mastocytosis, Medicine, Medicine (General), R5-920
Abstract

Abstract We report a de novo aleukemic form of MCL with a complex monosomic karyotype with LOH for multiple chromosomes and TP53 mutation. Additionally, whereas D816V KIT was not found, the c‐Kit transmembrane domain p.M541L variant was detected which is the most common SNP of KIT gene in humans with controversial pathogenic role. In these cases, it is crucial to perform a rapid broad molecular study for an accurate diagnosis which could help to initiate targeted therapy.

Published
2019
Full Text
View/download PDF

3. Microcytic anemia associated with mTOR or calcineurin inhibition: An unusual situation after allogeneic hematopoietic stem cell transplantation

Author

Irene García-Cadenas, Salvador Payán‐Pernía, Anna Monter Rovira, Angel F. Remacha, Rodrigo Martino Bofarull, Albert Esquirol Santfeliu, Jordi Sierra Gil, and Salut Brunet Mauri

Subjects
Male, business.industry, Calcineurin, TOR Serine-Threonine Kinases, medicine.medical_treatment, Microcytic anemia, Calcineurin Inhibitors, Biochemistry (medical), Clinical Biochemistry, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Anemia, Hematology, General Medicine, Hematopoietic stem cell transplantation, Allografts, medicine.disease, medicine, Cancer research, Humans, Female, business, PI3K/AKT/mTOR pathway
Published
2020
Full Text
View/download PDF

4. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

Author

Carlos, Montalbán, Antonio, Díaz-López, Alejandro, Martín, Mónica, Baile, José M, Sanchez, Juan M, Sancho, Olga, García, Silvana, Novelli, Anna, Monter-Rovira, Antonio, Salar, Mariana, Bastos, Antonio, Gutiérrez, Leyre, Bento, Raul, Córdoba, Teresa, Arquero, Sonia, González de Villambrosia, Gilberto, Barranco, Raquel, De Oña, Armando, López Guillermo, María J, Rodriguez Salazar, Juan F, Domínguez, Rubén, Fernández, José A, Queizan, José, Rodríguez, Victor, Abraira, Juan F, García, and María, Casanova

Subjects
Adult, Male, Cell of origin, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, Risk groups, Risk Factors, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Overall survival, cell of origin subtyping, Humans, Aged, Proportional hazards model, business.industry, GELTAMO-IPI, Hematology, Middle Aged, medicine.disease, Germinal Center, Prognosis, diffuse large B cell lymphoma, Survival Rate, 030220 oncology & carcinogenesis, immunohistochemistry, Immunohistochemistry, Female, Immunotherapy, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, Algorithm, Algorithms, Hans algorithm, 030215 immunology
Abstract

The Grupo Espanol de Linfomas y Trasplantes de Medula Osea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups in diffuse large B cell lymphoma (DLBCL) patients treated with immunochaemotherapy: low (LR), low-intermediate (LIR), high-intermediate (HIR), and high (HR). The present study explores the effect of GELTAMO-IPI in the DLBCL subtypes defined by the immunohistochaemistry-based Hans algorithm, Germinal Centre B (GCB) and non-GCB. A multivariate Cox regression model including GELTAMO-IPI risk groups, cell of origin (COO) subtypes and their product was developed to evaluate interaction between the two variables. The COO subtype was available in 839 patients (380 GCB; 459 non-GCB) and both the GELTAMO-IPI and the COO subtype in 780 (353 GCB; 427 non-GCB). There were no differences in 5-year overall survival (OS) between the two subtypes. The Cox model revealed interaction between the GELTAMO-IPI risk groups and the COO subtypes (P = 0·005), indicating that GELTAMO-IPI has a different effect in the two subtypes. Three risk groups were stratified in both COO subtypes: in the GCB subtype, LR, LIR and the combined HIR+HR had 5-year OS of 100%, 75% and 52%, respectively. In the non-GCB subtype, LR, the combined LIR+HIR and HR had a 5-year OS of, 97%, 82% and 35% respectively. GELTAMO-IPI identifies a genuine poor outcome group of patients in the DLBCL non-GCB subtype.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results